Step Pharma SAS
Step Pharma is a pioneering biotechnology company focused on developing highly selective, safe, and effective cancer treatments by targeting CTPS1, an enzyme critical for DNA and RNA synthesis in cancer cells. Their lead asset, STP938 (dencatistat), is a first-in-class, orally bioavailable CTPS1 inhibitor currently in clinical trials for blood cancers and solid tumours. The company's mission is to bring about a step change in cancer therapy by leveraging breakthrough science and genetic validation to develop targeted treatments with minimal side effects.
Industries
Nr. of Employees
small (1-50)
Products
Lead oral selective CTPS1 clinical candidate (lead compound)
An orally bioavailable, selective small-molecule inhibitor of the CTPS1 target developed for oncology indications and advanced into early-phase clinical evaluation with biomarker-enriched cohorts; under clinical development for haematological malignancies, selected solid tumours and essential thrombocythaemia.
Lead oral selective CTPS1 clinical candidate (lead compound)
An orally bioavailable, selective small-molecule inhibitor of the CTPS1 target developed for oncology indications and advanced into early-phase clinical evaluation with biomarker-enriched cohorts; under clinical development for haematological malignancies, selected solid tumours and essential thrombocythaemia.
Services
Translational research collaborations
Collaborative preclinical and translational research with academic and industry partners to validate target biology, generate proof-of-concept data, and explore combination strategies.
Predictive biomarker modelling partnerships
External partnerships to integrate experimental and clinical datasets using advanced statistical learning to prioritise biomarkers and inform patient selection for clinical studies.
Early-phase clinical trial operations
Operational delivery of Phase I/II clinical studies including site management, investigator coordination and execution of biomarker-selected cohorts.
Translational research collaborations
Collaborative preclinical and translational research with academic and industry partners to validate target biology, generate proof-of-concept data, and explore combination strategies.
Predictive biomarker modelling partnerships
External partnerships to integrate experimental and clinical datasets using advanced statistical learning to prioritise biomarkers and inform patient selection for clinical studies.
Early-phase clinical trial operations
Operational delivery of Phase I/II clinical studies including site management, investigator coordination and execution of biomarker-selected cohorts.
Expertise Areas
- Targeted small-molecule discovery against CTPS1
- Medicinal chemistry and lead optimisation
- Preclinical pharmacology and toxicology
- Translational biomarker discovery and genomic patient selection
Key Technologies
- Selective small-molecule inhibitor design
- Targeted inhibition of de novo pyrimidine synthesis (CTPS1)
- In vitro antiproliferative and cytotoxicity assays
- In vivo xenograft and transplant tumour models